Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDD-TURBT vs white-light TURBT plus Re-TURBT in NMIBC
2023-507307-64-00Phase 4Authorised
- Sponsor
- Sapienza University of Rome
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) comparing Primary PDD-TURBT with Hexvix with White-light TURBT plus Re-TURBT (standard of care) (2 arms). Primary endpoint: Early bladder cancer recurrence rate at first follow-up cystoscopy. Planned start Feb 2024; status: authorised.
02
Drugs
hexaminolevulinate
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2023-507307-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507307-64-00.